Taking a shot at Celltech

Article Abstract:

Celltech has developed into a pharmaceuticals concern with new treatments for the protection of the immune system. Alliances with major drugs companies have been set up by Peter Fellner, the company's chief executive. This has helped with costs and fees. The company has sold Celltech Biologics for 80 million pounds sterling and this means that fund raising is not needed. Research will be boosted by using the disposal cash. The company forecasts a break-even point in 1997 to 1998 though this is dependent on how a new septic shock treatment progresses.

---

profile: Peter Fellner of Celltech

Article Abstract:

Peter Fellner, Chief Exec of UK biotechnology firm Celltech, is a frank and patient manager who shuns the hype which has surrounded high-tech stocks. Controversially, Fellner said in 2000 that Celltech's share price was too high, and he now believes the shares are undervalued.

Biotechnology industry, Biotechnology industries, Interview, Fellner, Peter

---

Celltech

Article Abstract:

Celltech is seen as a key holding in the pharmaceutical industry and its mix of drugs should provide security for the company's stocks.

Similar abstracts:

• Abstracts: Making a mint from technofear. Rerating overdue. CMG
• Abstracts: Embargoes should go, says tech reporter. Editor says releases are useless. PR pros must harness power of 'Net
• Abstracts: Taking a look at the telecoms gift horse. SBC Communications
• Abstracts: It's good to talk about telecoms. BT calls time on debts. Telecoms in the fast lane
• Abstracts: Single market, multiple problems. The integrated path to success. Can you risk it?

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.